Form 4: Tectonic Therapeutic Director Springer Reports Acquisition of Shares and Stock Options Following Merger

Director Timothy A. Springer reports acquiring shares and stock options in Tectonic Therapeutic following the merger with AVROBIO, Inc.

Summary

• Timothy A. Springer, a director and 10% owner of Tectonic Therapeutic, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 20, 2024, Springer acquired 2,692,005 shares of common stock directly as a result of the merger between Tectonic and AVROBIO.
• He also acquired 1,551,116 shares indirectly through TAS Partners, LLC, where he is the sole managing member.
• Additionally, Springer acquired stock options for 11,760 shares of common stock with an exercise price of $16.80, vesting over three years.
• The merger involved AVROBIO acquiring Tectonic, with each share of Tectonic common stock converted into 0.534419990 shares of AVROBIO's common stock after a 1-for-12 reverse stock split; AVROBIO was then renamed Tectonic Therapeutic, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects a standard procedure following a merger, with a director increasing their stake in the company through stock and options. This suggests confidence, but it's a routine disclosure.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future after the merger.

Future Outlook

The document does not contain explicit forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Mergers and acquisitions are common in the biotech industry as companies seek to expand their pipelines and capabilities. This merger allows AVROBIO (now Tectonic Therapeutic) to potentially leverage Tectonic's therapeutic platform.

Comparison to Industry Standards

• Stock option vesting schedules are standard practice in the biotech industry to incentivize long-term commitment from key personnel.
• Merger terms, including conversion ratios and reverse stock splits, are negotiated based on the relative valuations of the merging companies.
• Form 4 filings are a standard regulatory requirement for insiders reporting changes in beneficial ownership.

Stakeholder Impact

• Shareholders are impacted by the merger and the subsequent changes in share ownership.
• Employees of both AVROBIO and Tectonic Therapeutic are affected by the integration of the two companies.

Key Dates